Literature DB >> 27434652

Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome.

Ozlem Gursoy Calan1, Mehmet Calan2, Pinar Yesil Senses3, Gokcen Unal Kocabas2, Ebru Ozden4, Kerime R Sari4, Merve Kocar4, Cetin Imamoglu5, Yasar M Senses3, Giray Bozkaya6, Oktay Bilgir4.   

Abstract

CONTEXT: Adipsin, a protein secreted mainly from the adipose tissue, is a structural homologous of complement factor D, a rate-limiting enzyme of the alternative complement system. Growing evidence suggests that the alternative complement system plays a role both in the regulation of energy homoeostasis and in the atherosclerosis. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease.
OBJECTIVE: To ascertain whether circulating adipsin levels are altered in women with PCOS, and whether there is an association between adipsin and metabolic parameters or carotid intima media thickness (CIMT). PARTICIPANTS: A total of 144 women with PCOS and 144 age- and BMI-matched controls without PCOS were recruited for this cross-sectional study. MAIN OUTCOME MEASURES: Circulating adipsin levels were measured using ELISA. Metabolic, hormonal parameters and CIMT were also determined.
RESULTS: Adipsin levels were significantly elevated in women with PCOS compared with controls (91·52 ± 14·11 vs 60·31 ± 9·71 ng/ml, P < 0·001). Adipsin positively correlated with BMI, homoeostasis model assessment of insulin resistance (HOMA-IR), free testosterone, high-sensitivity C-reactive protein (hs-CRP) and CIMT in both groups. Multivariate logistic regression analyses revealed that the odds ratio for PCOS was 3·25 for patients in the highest quartile of adipsin compared with those in the lowest quartile (OR=3·25, 95% CI=2·64-4·00, P = 0·016). Our findings further indicate that BMI, HOMA-IR, hs-CRP and free testosterone are independent factors influencing serum adipsin levels and that adipsin is an independent predictor for CIMT.
CONCLUSION: Circulating adipsin levels are significantly higher in women with PCOS, and the peptide is closely related to increased cardiovascular risk and metabolic disturbances.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27434652     DOI: 10.1111/cen.13157

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  19 in total

1.  Plasma levels of adipokines in patients with Alzheimer's disease - where is the "breaking point" in Alzheimer's disease pathogenesis?

Authors:  M Vaňková; G Vacínová; J Včelák; D Vejražková; P Lukášová; R Rusina; I Holmerová; E Jarolímová; H Vaňková; B Bendlová
Journal:  Physiol Res       Date:  2020-09-30       Impact factor: 1.881

2.  Adiposity Measurements and Metabolic Syndrome Are Linked Through Circulating Neuregulin 4 and Adipsin Levels in Obese Adults.

Authors:  Dan Guo; Jianfang Liu; Peizhen Zhang; Xiaoyu Yang; Deying Liu; Jiayang Lin; Xueyun Wei; Bingyan Xu; Chensihan Huang; Xuan Zhou; Fei Teng; Hong Zhu; Huijie Zhang
Journal:  Front Physiol       Date:  2021-05-04       Impact factor: 4.566

3.  Association between serum adipsin and plaque vulnerability determined by optical coherence tomography in patients with coronary artery disease.

Authors:  Renhua Sun; Yong Qiao; Gaoliang Yan; Dong Wang; Wenjie Zuo; Zhenjun Ji; Xiaoguo Zhang; Yuyu Yao; Genshan Ma; Chengchun Tang
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

Review 4.  Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome.

Authors:  Krystallenia I Alexandraki; Eleni A Kandaraki; Kalliopi-Anna Poulia; Christina Piperi; Eirini Papadimitriou; Theodoros G Papaioannou
Journal:  touchREV Endocrinol       Date:  2021-04-28

5.  Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance.

Authors:  Qing Zhou; Qian Ge; Yao Ding; Hua Qu; Huili Wei; Rui Wu; Lu Yao; Qianping Wei; Zhengping Feng; Jian Long; Huacong Deng
Journal:  J Diabetes Investig       Date:  2018-03-22       Impact factor: 4.232

6.  IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study.

Authors:  Piero Ruscitti; Francesco Ursini; Paola Cipriani; Marta Greco; Saverio Alvaro; Liakouli Vasiliki; Paola Di Benedetto; Francesco Carubbi; Onorina Berardicurti; Elio Gulletta; Giovambattista De Sarro; Roberto Giacomelli
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

7.  Comparative omics and feeding manipulations in chicken indicate a shift of the endocrine role of visceral fat towards reproduction.

Authors:  Susanne Bornelöv; Eyal Seroussi; Sara Yosefi; Sharon Benjamini; Shoval Miyara; Mark Ruzal; Manfred Grabherr; Nima Rafati; Anna-Maja Molin; Ken Pendavis; Shane C Burgess; Leif Andersson; Miriam Friedman-Einat
Journal:  BMC Genomics       Date:  2018-04-26       Impact factor: 3.969

8.  Protein Biomarkers of Cardiovascular Disease and Mortality in the Community.

Authors:  Jennifer E Ho; Asya Lyass; Paul Courchesne; George Chen; Chunyu Liu; Xiaoyan Yin; Shih-Jen Hwang; Joseph M Massaro; Martin G Larson; Daniel Levy
Journal:  J Am Heart Assoc       Date:  2018-07-13       Impact factor: 5.501

9.  Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study.

Authors:  Dan Guo; Yang Yuan; Rong Huang; Sai Tian; Jiaqi Wang; Hongyan Lin; Ke An; Jin Han; Shaohua Wang
Journal:  BMC Endocr Disord       Date:  2019-10-24       Impact factor: 2.763

10.  Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease.

Authors:  Tomohiro Ohtsuki; Kimio Satoh; Toru Shimizu; Shohei Ikeda; Nobuhiro Kikuchi; Taijyu Satoh; Ryo Kurosawa; Masamichi Nogi; Shinichiro Sunamura; Nobuhiro Yaoita; Junichi Omura; Tatsuo Aoki; Shunsuke Tatebe; Koichiro Sugimura; Jun Takahashi; Satoshi Miyata; Hiroaki Shimokawa
Journal:  J Am Heart Assoc       Date:  2019-11-22       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.